U.S. markets closed

Is a Surprise Coming for Neurocrine Biosciences (NBIX) This Earnings Season?

Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and Neurocrine Biosciences, Inc. NBIX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Neurocrine Biosciences is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for NBIX in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 67 cents per share for NBIX, compared to a broader Zacks Consensus Estimate of 55 cents per share. This suggests that analysts have very recently bumped up their estimates for NBIX, giving the stock a Zacks Earnings ESP of +22.02% heading into earnings season.

Neurocrine Biosciences, Inc. Price and EPS Surprise

Neurocrine Biosciences, Inc. Price and EPS Surprise

Neurocrine Biosciences, Inc. price-eps-surprise | Neurocrine Biosciences, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that NBIX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Clearly, recent earnings estimate revisions suggest that good things are ahead for Neurocrine Biosciences, and that a beat might be in the cards for the upcoming report. 

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>  


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research